Source disclosure: February 12, 2026
Kidswell Bio Corporation [4584.T]
TOKYO, Feb 12, 2026 (JCN Newswire via COMTEX) - Kidswell Bio Corporation (Tokyo Stock Exchange: 4584), a leading biotechnology company focused on creating value through innovative healthcare solutions, today released its earnings presentation for the third quarter of fiscal year 2025. The presentation highlights the company's progress and strategic initiatives aimed at enhancing care for children, families, and society.
The company reported several key performance indicators during the period. Revenue for the third quarter reached ¥15 billion, marking an increase of 12% compared to the same period last year. Operating income stood at ¥3 billion, reflecting a robust growth rate of 15%. Additionally, net income for the quarter was reported at ¥2.2 billion, up by 17% from the previous year. These figures underscore Kidswell Bio's continued success in expanding its market presence and operational efficiency.
Kidswell Bio's agenda for the presentation includes detailed discussions on two core business segments: the biosimilar business and cell therapy (S-Quatre). The biosimilar segment has seen significant advancements, with ongoing clinical trials for multiple products nearing completion. Meanwhile, the S-Quatre cell therapy initiative is progressing well, with promising results from recent studies that could lead to new treatment options for various diseases. The company also outlined its comprehensive strategy for future growth and engagement in investor relations activities designed to enhance transparency and communication with stakeholders.
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms • Original filing